Concepedia

Chris P. Pescott

CP

Statistics

Publications

5

Citations

91

H-Index

5

Active since

2014

Affiliations

Merck KGaA, Darmstadt (Germany)(Current)

Amsterdam UMC Location Vrije Universiteit Amsterdam

University Medical Center Utrecht

Erasmus University Rotterdam

Erasmus MC

Chris P. Pescott is an author at Merck KGaA, Darmstadt (Germany) specializing in pharmacoeconomics, oncology, and medicine.

ORCID

Publications per year

2014–2020

5

Publications

5

Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma

Ash Bullement, Anna Willis, Amerah Amin et al. · PharmacoEconomics - Open · 2019 · 27 citations · Full text

, , +17

Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands

Naomi van der Linden, Jan Buter, Chris P. Pescott et al. · European Archives of Oto-Rhino-Laryngology · 2015 · 24 citations · Full text

, , +17

Economic Evaluation of Three Frequently Used Gonadotrophins in Assisted Reproduction Techniques in the Management of Infertility in the Netherlands

Vassilis Fragoulakis, Chris P. Pescott, J Smeenk et al. · Applied Health Economics and Health Policy · 2016 · 14 citations

, , +15

Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of<i>RAS</i>wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study

Sebastian Stintzing, I. van Oostrum, Chris P. Pescott et al. · Journal of Medical Economics · 2020 · 14 citations · Full text

, , +17

Real-world cost-effectiveness of cetuximab in locally advanced squamous cell carcinoma of the head and neck

Naomi van der Linden, C.W.M. van Gils, Chris P. Pescott et al. · European Archives of Oto-Rhino-Laryngology · 2014 · 12 citations · Full text

, , +7

1–5 of 5